• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    6/20/24 8:05:58 AM ET
    $CNSP
    $CYCN
    $GOVX
    $INMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNSP alert in real time by email

    Gainers

    • Tempest Therapeutics (NASDAQ:TPST) shares rose 32.8% to $3.79 during Thursday's pre-market session. The company's market cap stands at $84.0 million.
    • Neurogene (NASDAQ:NGNE) shares rose 31.92% to $40.0. The company's market cap stands at $519.2 million.
    • Geovax Labs (NASDAQ:GOVX) shares rose 28.94% to $2.45. The company's market cap stands at $6.1 million.
    • SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 24.03% to $3.2. The market value of their outstanding shares is at $29.5 million.
    • Trevena (NASDAQ:TRVN) stock rose 23.33% to $0.44. The market value of their outstanding shares is at $8.0 million.
    • Molecular Partners (NASDAQ:MOLN) stock rose 22.23% to $9.73. The company's market cap stands at $322.8 million.

    Losers

    • Mustang Bio (NASDAQ:MBIO) stock fell 27.4% to $0.62 during Thursday's pre-market session. The market value of their outstanding shares is at $17.4 million.
    • Mobile-health Network (NASDAQ:MNDR) shares declined by 9.25% to $1.32. The market value of their outstanding shares is at $45.0 million.
    • Cyclerion Therapeutics (NASDAQ:CYCN) stock decreased by 9.05% to $2.01. The market value of their outstanding shares is at $5.0 million.
    • INmune Bio (NASDAQ:INMB) shares declined by 8.97% to $7.01. The company's market cap stands at $138.6 million.
    • CNS Pharma (NASDAQ:CNSP) stock fell 8.92% to $2.2. The market value of their outstanding shares is at $1.8 million.
    • Praxis Precision Medicine (NASDAQ:PRAX) shares decreased by 8.65% to $34.43. The market value of their outstanding shares is at $589.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CNSP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CNSP
    $CYCN
    $GOVX
    $INMB

    CompanyDatePrice TargetRatingAnalyst
    Praxis Precision Medicines Inc.
    $PRAX
    2/24/2026$500.00Outperform
    Wolfe Research
    GeoVax Labs Inc.
    $GOVX
    2/19/2026Buy → Hold
    D. Boral Capital
    Praxis Precision Medicines Inc.
    $PRAX
    2/2/2026$282.00Equal Weight
    Wells Fargo
    Molecular Partners AG
    $MOLN
    1/27/2026$13.00Buy
    H.C. Wainwright
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    SAB Biotherapeutics Inc.
    $SABS
    12/19/2025$15.00Buy
    Guggenheim
    Praxis Precision Medicines Inc.
    $PRAX
    12/15/2025$250.00 → $750.00Outperform
    Oppenheimer
    Praxis Precision Medicines Inc.
    $PRAX
    11/19/2025$424.00Buy
    BTIG Research
    More analyst ratings

    $CNSP
    $CYCN
    $GOVX
    $INMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Praxis Precision Medicines with a new price target

    Wolfe Research initiated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $500.00

    2/24/26 7:55:37 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeoVax Labs downgraded by D. Boral Capital

    D. Boral Capital downgraded GeoVax Labs from Buy to Hold

    2/19/26 8:44:06 AM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Praxis Precision Medicines with a new price target

    Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00

    2/2/26 6:51:57 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GOVX
    $INMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jin David bought $238 worth of shares (247 units at $0.96), increasing direct ownership by 633% to 286 units (SEC Form 4)

    4 - MUSTANG BIO, INC. (0001680048) (Issuer)

    12/30/25 4:15:14 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Mckee Kelly T. Jr. bought $742 worth of shares (1,107 units at $0.67), increasing direct ownership by 46% to 3,494 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    8/8/25 3:13:56 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

    4 - GeoVax Labs, Inc. (0000832489) (Issuer)

    4/11/25 1:23:33 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GOVX
    $INMB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results

    ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced its attendance and presentations at upcoming investor conferences. Molecular Partners will also issue its full-year 2025 financial report, along with its Annual Report, on March 12, 2026. Details of the events: TD Cowen 46th Annual Health Care ConferenceBoston, MA, March 2-4, 2026Molecular Partners CEO Patrick Amstutz will take part in a fireside chat on Monday, March 2 at 2.30-3.00 pm E

    2/26/26 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics

    ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it has entered into an agreement with Eckert & Ziegler, leading specialist in isotope-related components for nuclear medicine and radiation therapy, to enable the development and manufacturing of Radio-DARPin therapeutics. "We are pleased to work with Eckert & Ziegler, a global leader in radiopharmaceutical manufacturing. This agreement will expand the potential of Radio-DARPins as vecto

    2/26/26 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026

    100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease36 patients with relapsed/refractory multiple myeloma treated to date across two studiesTempest plans to submit a U.S. IND and, subject to clearance, initiate a U.S. registrational study in 2026 BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced cell therapy and small molecule product ca

    2/25/26 7:59:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GOVX
    $INMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Cobb Stuart was granted 16,500 shares, increasing direct ownership by 79% to 37,294 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    2/24/26 6:49:39 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Jordan Julie was granted 4,900 shares, increasing direct ownership by 58% to 13,300 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    2/24/26 6:49:24 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CFO Cvijic Christine Mikail was granted 22,000 shares, increasing direct ownership by 24% to 114,643 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    2/24/26 6:49:01 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GOVX
    $INMB
    SEC Filings

    View All

    SEC Form 8-K filed by Tempest Therapeutics Inc.

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    2/25/26 8:09:00 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Inmune Bio, Inc. (0001711754) (Filer)

    2/23/26 4:05:29 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INmune Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Inmune Bio, Inc. (0001711754) (Filer)

    2/19/26 4:00:25 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CNSP
    $CYCN
    $GOVX
    $INMB
    Leadership Updates

    Live Leadership Updates

    View All

    Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

    –Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126

    2/17/26 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. "These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage developm

    1/8/26 4:45:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GOVX
    $INMB
    Financials

    Live finance-specific insights

    View All

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

    Specific tumor accumulation and attractive biodistribution highly supportive of MP0712 clinical development for treatment of DLL3-expressing cancersDosimetry data highlight Radio-DARPins as vector for precise delivery of potent alpha-emitting isotopes to tumorsMP0712 Phase 1/2a study open in U.S. with initial clinical data expected in 2026Molecular Partners to host conference call February 2 at 8AM ET (2PM CET), joined by renowned nuclear medicine expert Prof. Ken Herrmann, M.D. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company deve

    2/2/26 1:00:00 AM ET
    $MOLN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

    BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therapeutics to fight cancer, today announced the record date of January 30, 2026 (the "Record Date") for the distribution of warrants to purchase Tempest common stock ("Warrants") as a dividend (the "Warrant Dividends"), as contemplated by Tempest's previously announced Asset Purchase Agreement (the "Asset Purchase Agreement") with Erigen LLC and Factor Bioscience Inc. The distribution of the Warrant Dividends is expected to be Tuesday, February 3, 2026, but is subject to the prior satisfaction of c

    1/20/26 5:20:02 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GOVX
    $INMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neurogene Inc.

    SC 13G - Neurogene Inc. (0001404644) (Subject)

    12/11/24 4:05:09 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

    SC 13G/A - Neurogene Inc. (0001404644) (Subject)

    11/27/24 4:25:10 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 7:53:30 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CNSP
    $CYCN
    $GOVX
    $INMB
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Breaking: Stock Acquired at INmune Bio Inc. on Jun 26

    Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

    6/26/24 2:54:12 PM ET
    $INMB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care